| Antibodies - Accelerated Contract Research with the Disruptive Power of Simoa® |
|
|
|
|
| |
|
| |
The latest antibodies news from News Medical |
|
|
|
 | | |  High bioactivity target proteins for ADCs
ACROBiosystems has developed a series of ADCs target proteins with different species and tags suitable for immunization, antibody screening, affinity testing, cell-based assay analysis, and other applications. ACROBiosystems is committed to assisting you in drug development, and all SPR&BLI&ELISA protocols are available for free.
| |
|
|
| | | | |  B cell development begins in the fetal liver. From 12 weeks onwards, B cell development continues in hematopoietic stem cells in the bone marrow. | | | | |  A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. | | | | |  A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments. | | | | |  A new study reports a very promising anti-SARS-CoV-2 monoclonal antibody, HB27, that appears to have two distinct mechanisms of action inhibiting the virus-host cell interaction and subsequent infection. | |
|
|
|
|
|
|
|
